AtriCure Enrolls First Patient in BoxX-NoAF Study
AtriCure (Nasdaq:ATRC) announced the enrollment of the first patient in its BoxX-NoAF clinical trial, evaluating its cardiac therapy technologies.
The BoxX-NoAF trial aims to define clinical practice and treatment guidelines for reducing post-operative AFib (POAF) and longer-term clinical AFib in elevated-risk cardiac surgery patients.
- The study investigates concomitant surgical ablation with left atrial appendage (LAA) management.
- Investigators seek to determine if this approach reduces the occurrence of new-onset AFib POAF compared to no treatment.
Anthony Rongione treated the first patient at Orlando Health Heart and Vascular Institute.
No direct quote available in the text.
Author's summary: AtriCure starts BoxX-NoAF trial to reduce AFib in cardiac surgery patients.
More News
- Congress gridlocked on key issues as year-end deadline looms
- Après la tentative de coup d'Etat au Bénin, la menace du pouvoir kaki plus présente que jamais en Afrique
- Benin Rejects Claims of a Coup by Opposition Soldiers
- Full steam ahead for good causes at train station's big birthday bash
- Heavy rain gridlocks KL traffic
- Gridlocked Halloween, 2025, @kaltgatzke flashbang film. I ...
- Commuters hot under the collar as snow, ice gridlock roads across Seoul
- Benin coup attempt foiled by loyalist troops, interior minister says
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- PREDICTED TEAM: How Scorchers will line up for BBL opener